Please wait while we load the requested 10-K report or click the link below:
https://last10k.com/sec-filings/report/1411906/000155837019002244/ampe-20181231x10k.htm
SEC Filings
AMPE Annual Reports
AMPE Quarterly Reports
10-Q Quarterly Report August 2022
10-Q Quarterly Report May 2022
10-Q Quarterly Report November 2021
10-Q Quarterly Report August 2021
10-Q Quarterly Report May 2021
10-Q Quarterly Report November 2020
10-Q Quarterly Report July 2020
10-Q Quarterly Report May 2020
10-Q Quarterly Report November 2019
10-Q Quarterly Report August 2019
10-Q Quarterly Report August 2022
10-Q Quarterly Report May 2022
10-Q Quarterly Report November 2021
10-Q Quarterly Report August 2021
10-Q Quarterly Report May 2021
10-Q Quarterly Report November 2020
10-Q Quarterly Report July 2020
10-Q Quarterly Report May 2020
10-Q Quarterly Report November 2019
10-Q Quarterly Report August 2019
AMPE Corporate News
Vote of Security Holders August 2022
Financial Exhibit
New Costs
Other Events
Regulated Disclosure August 2022
Listing Status June 2022
Financial Exhibit
Other Events June 2022
Event for Officers June 2022
Earnings Release
Financial Exhibit
Other Events May 2022
Financial Exhibit
Regulated Disclosure April 2022
Financial Exhibit
Other Events April 2022
Earnings Release
Financial Exhibit March 2022
Financial Exhibit
Other Events March 2022
Vote of Security Holders
August 2022
Financial Exhibit
New Costs
Other Events
Regulated Disclosure
New Costs
Other Events
Regulated Disclosure
August 2022
Listing Status
June 2022
Financial Exhibit
Other Events
Other Events
June 2022
Event for Officers
June 2022
Earnings Release
Financial Exhibit
Other Events
Financial Exhibit
Other Events
May 2022
Financial Exhibit
Regulated Disclosure
Regulated Disclosure
April 2022
Financial Exhibit
Other Events
Other Events
April 2022
Earnings Release
Financial Exhibit
Financial Exhibit
March 2022
Financial Exhibit
Other Events
Other Events
March 2022
Last10K.com | 10-K Annual Report Mon Mar 18 2019
Document And Entity Information - USD ($) $ in Millions | 12 Months Ended | ||
|---|---|---|---|
Dec. 31, 2018 | Mar. 01, 2019 | Jun. 30, 2018 | |
| Document And Entity Information [Abstract] | |||
| Document Type | 10-K | ||
| Amendment Flag | false | ||
| Document Period End Date | Dec. 31, 2018 | ||
| Document Fiscal Year Focus | 2018 | ||
| Document Fiscal Period Focus | FY | ||
| Entity Voluntary Filers | No | ||
| Entity Current Reporting Status | Yes | ||
| Entity Registrant Name | Ampio Pharmaceuticals, Inc. | ||
| Entity Central Index Key | 0001411906 | ||
| Current Fiscal Year End Date | --12-31 | ||
| Entity Filer Category | Accelerated Filer | ||
| Trading Symbol | AMPE | ||
| Entity Common Stock, Shares Outstanding | 111,127,878 | ||
| Entity Well-known Seasoned Issuer | No | ||
| Entity Public Float | $ 174.5 | ||
| Entity Emerging Growth Company | false | ||
| Entity Small Business | true | ||
| Entity Shell Company | false |
View differences made from one year to another to evaluate Ampio Pharmaceuticals, Inc.'s financial trajectory
Compare this 10-K Annual Report to its predecessor by reading our highlights to see what text and tables were removed , added and changed by Ampio Pharmaceuticals, Inc..
Assess how Ampio Pharmaceuticals, Inc.'s management team is paid from their Annual Proxy
Ampio Pharmaceuticals, Inc.'s Definitive Proxy Statement (Form DEF 14A) filed after their 2019 10-K Annual Report includes:
- Voting Procedures
- Board Members
- Executive Team
- Salaries, Bonuses, Perks
- Peers / Competitors
SEC Filing Tools
Rating
Learn More
Filter Sentiment:
Filter Category:
Filter Subcategory:
-
Financial - Expense Highlight
In addition, the sponsored research related party expense also contributed to the decrease in the research and development costs due to the termination of the Trauma Research Agreement during the 2017 period with no costs incurred during the 2018 period.
-
Financial - Expense Highlight
These costs relate solely to research and development without an allocation of general and administrative expenses and are summarized as follows: Comparison of Years Ended December 31, 2018 and 2017 Research and development costs decreased $3.6 million, or 34.5%, for the year ended December 31, 2018 compared to the same period in 2017.
-
Financial - Expense Highlight
Occupancy, travel and other expense also decreased as we did not incur costs related to media outreach during the 2018 period compared to the 2017 period.
-
Financial - Expense Highlight
The decrease is primarily attributable to lower costs related to clinical trials and sponsored research expense, labor costs and stock-based compensation, as well as the sponsored research-related party.
-
Financial - Expense Highlight
The operating expenses decreased $4.5 million from the 2017 period to the 2018 period primarily due to a $3.6 million decrease in research and development costs and a $900,000 decrease in general and administrative costs, which is further explained below.
-
Financial - Expense
These costs are summarized as...Read more
-
Financial - Expense
In general, we believe that...Read more
-
Other - Other
The net loss was primarily...Read more
-
Revenue - Product
We also received gross proceeds...Read more
-
Financial - Expense
With high priced options becoming...Read more
-
Financial - Expense
In addition, the number of...Read more
-
Other - Other
The increase in our stock...Read more
-
Financial - Expense
The elimination of the PTO...Read more
-
Financial - Expense
The elimination of the PTO...Read more
-
Revenue - Geography
On November 9, 2017, we...Read more
-
Revenue - Product
Although we have raised net...Read more
-
Financial - Expense
Our clinical trial costs decreased...Read more
-
Revenue - Geography
We submitted a plan on...Read more
-
Other - Other
The investor warrant exercises and...Read more
-
Other - Other
The increase in our stock...Read more
-
Legal - Other
There was an increase in...Read more
-
Financial - Shares
We intend to evaluate the...Read more
-
Financial - Expense
General and administrative expenses consist...Read more
-
Other - Other
In addition, Dr. Bar-Or retired...Read more
-
Financial - Expense
As noted in the Research...Read more
-
Other - Other
The decrease in our stock...Read more
-
Other - Other
However, we intend to try...Read more
Financial Statements, Disclosures and Schedules
Inside this 10-K Annual Report
Document And Entity Information
Balance Sheets
Balance Sheets (Parenthetical)
Statements Of Cash Flows
Statements Of Operations
Statements Of Stockholders' Equity (Deficit)
Statements Of Stockholders' Equity (Deficit) (Parenthetical)
Basis Of Presentation
Commitments And Contingencies
Commitments And Contingencies (Tables)
Commitments And Contingencies - Additional Information (Detail)
Commitments And Contingencies - Rent Expense (Detail)
Commitments And Contingencies - Summary Of Commitments And Contingencies (Detail)
Common Stock
Common Stock (Capital Stock Narrative) (Details)
Common Stock (Common Stock Issued For Services) (Details)
Common Stock (Confidentially Marketed Public Offering Narrative) (Details)
Common Stock (Controlled Equity Offering) (Details)
Common Stock (Registered Direct Offering Narrative) (Details)
Common Stock (Shelf Registration Narrative) (Details)
Employee Benefit Plan
Equity Instruments
Equity Instruments (Tables)
Equity Instruments - Assumptions For Warrants Issued (Detail)
Equity Instruments - Assumptions Used In Computing Fair Value Of All Options Granted (Detail)
Equity Instruments - Options, Additional Information (Detail)
Equity Instruments - Stock Option Activity (Detail)
Equity Instruments - Summary Of Stock Options Outstanding And Exercisable (Detail)
Equity Instruments - Summary Of Stock-Based Compensation Expense (Detail)
Equity Instruments - Warrants Issued In Conjunction With Its Senior Convertible Debentures (Detail)
Equity Instruments - Warrants, Additional Information (Detail)
Fair Value Considerations
Fair Value Considerations (Tables)
Fair Value Considerations - Financial Assets And Liabilities (Detail)
Fair Value Considerations - Sets Forth A Reconciliation Of Changes (Detail)
Going Concern
Going Concern - Additional Information (Detail)
Income Taxes
Income Taxes (Tables)
Income Taxes - Additional Information (Detail)
Income Taxes - Deferred Tax Assets And Liabilities (Detail)
Income Taxes - Reconciliation Of Effective Tax Rate (Detail)
Litigation
Related Party Transactions
Related Party Transactions - Additional Information (Detail)
Subsequent Events
Subsequent Events - Additional Information (Detail)
Summary Of Significant Accounting Policies
Summary Of Significant Accounting Policies (Policies)
Summary Of Significant Accounting Policies (Tables)
Summary Of Significant Accounting Policies - Additional Information (Detail)
Summary Of Significant Accounting Policies - Depreciation Expenses (Detail)
Summary Of Significant Accounting Policies - Potentially Dilutive Securities, Excluded (Detail)
Summary Of Significant Accounting Policies - Schedule Of Fixed Assets (Detail)
Material Contracts, Statements, Certifications & more
Ampio Pharmaceuticals, Inc. provided additional information to their SEC Filing as exhibits
Ticker: AMPE
CIK: 1411906
Form Type: 10-K Annual Report
Accession Number: 0001558370-19-002244
Submitted to the SEC: Mon Mar 18 2019 12:42:50 PM EST
Accepted by the SEC: Mon Mar 18 2019
Period: Monday, December 31, 2018
Industry: Pharmaceutical Preparations
External Resources:
Stock Quote
Social Media
Bookmark the Permalink: https://last10k.com/sec-filings/ampe/0001558370-19-002244.htm
SEC Filing Exhibit
PDF Download
Loading SEC Filing Exhibit...
Excel DownloadLoading SEC Filing Financial Summary...